Cite
Cost-effectiveness of Preemptive Therapy Versus Prophylaxis in a Randomized Clinical Trial for the Prevention of Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors.
MLA
Singh, Nina, et al. “Cost-Effectiveness of Preemptive Therapy Versus Prophylaxis in a Randomized Clinical Trial for the Prevention of Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors.” Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, vol. 73, no. 9, Nov. 2021, pp. e2739–45. EBSCOhost, https://doi.org/10.1093/cid/ciaa1051.
APA
Singh, N., Winston, D. J., Razonable, R. R., Lyon, G. M., Silveira, F. P., Wagener, M. M., & Limaye, A. P. (2021). Cost-effectiveness of Preemptive Therapy Versus Prophylaxis in a Randomized Clinical Trial for the Prevention of Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 73(9), e2739–e2745. https://doi.org/10.1093/cid/ciaa1051
Chicago
Singh, Nina, Drew J Winston, Raymund R Razonable, G Marshall Lyon, Fernanda P Silveira, Marilyn M Wagener, and Ajit P Limaye. 2021. “Cost-Effectiveness of Preemptive Therapy Versus Prophylaxis in a Randomized Clinical Trial for the Prevention of Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors.” Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 73 (9): e2739–45. doi:10.1093/cid/ciaa1051.